Aptahem AB (publ) (APTA.ST)
Aptahem AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Malmö, SN, SE. The stock last traded at $0.36, up 4.65% on the session, giving a market capitalisation of $9.3M. Its beta of 0.64 implies it has historically moved less than the broad market.
Aptahem AB (publ) is a clinical-stage biotechnology company dedicated to creating aptamer-based pharmaceuticals aimed at treating acute, life-threatening medical conditions. Its flagship drug candidate, Apta-1, is currently in preclinical development, designed to reduce the mortality rate in sepsis patients by combating organ and tissue damage. The company has established partnerships with several academic institutions, notably through a consortium comprising Örebro University, Seattle Children's Research Institute, and University Health Network. Founded in 2014, Aptahem AB (publ) operates from its headquarters in Malmö, Sweden.
Aptahem AB (publ) is most often compared with the following Healthcare names: